Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2013, Article ID 683948, 5 pages
http://dx.doi.org/10.1155/2013/683948
Case Report

Granulomatous Lung Disease Requiring Mechanical Ventilation Induced by a Single Application of Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Case Report

1Department of Medicine 1, University Hospital Erlangen, Ulmenweg 18, 91054 Erlangen, Germany
2Radiological Institute, University Hospital Erlangen, Maximiliansplatz 1, 91054 Erlangen, Germany
3Institute of Pathology, University Hospital Erlangen, Krankenhausstraße 12, 91054 Erlangen, Germany
4Department of Surgery, University Hospital Erlangen, Krankenhausstraße 12, 91054 Erlangen, Germany

Received 17 February 2013; Accepted 23 March 2013

Academic Editors: R. Martinez, S. Ohno, and R. Yamamoto

Copyright © 2013 Dane Wildner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Tournigand, T. André, E. Achille et al., “FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study,” Journal of Clinical Oncology, vol. 22, no. 2, pp. 229–237, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Grothey and D. Sargent, “Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line,” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9441–9442, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Link, K. Happich, I. Schirner et al., “Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC),” Anticancer Research, vol. 24, no. 1, pp. 385–391, 2004. View at Google Scholar · View at Scopus
  4. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Cunningham, Y. Humblet, S. Siena et al., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer,” New England Journal of Medicine, vol. 351, no. 4, pp. 337–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Wein, C. Riedel, F. Köckerling et al., “Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid,” Annals of Oncology, vol. 12, no. 12, pp. 1721–1727, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Albrecht, F. Boxberger, K. Wolff et al., “Palliative first-line treatment with weekly high-dose 5-fluorouracil and sodium folinic acid (s-FA) (AIO-schedule) as 24h-infusion plus biweekly oxaliplatin (ox) in patients with definitively non-resectable metastatic colorectal cancer (CRC) following secondary (sec.) metastatic resection: an interdisciplinary phase II-trial,” Journal of Clinical Oncology, vol. 27, supplement, abstract e15073, 2009. View at Google Scholar
  8. R. K. Ramanathan, J. W. Clark, N. E. Kemeny et al., “Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer,” Journal of Clinical Oncology, vol. 21, no. 15, pp. 2904–2911, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. R. M. Goldberg, D. J. Sargent, R. F. Morton et al., “A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 23–30, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Cassidy and J. L. Misset, “Oxaliplatin-related side effects: characteristics and management,” Seminars in Oncology, vol. 29, no. 5, supplement 15, pp. 11–20, 2002. View at Google Scholar · View at Scopus
  11. F. Stickel, B. Jüngert, V. Brueckl et al., “Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin,” Anti-Cancer Drugs, vol. 14, no. 9, pp. 745–749, 2003. View at Google Scholar · View at Scopus
  12. R. Trisolini, L. Lazzari Agli, D. Tassinari et al., “Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy,” European Respiratory Journal, vol. 18, no. 1, pp. 243–245, 2001. View at Google Scholar · View at Scopus
  13. F. Gagnadoux, C. Roiron, E. Carrie, L. Monnier-Cholley, and B. Lebeau, “Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer,” American Journal of Clinical Oncology, vol. 25, no. 4, pp. 388–390, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. X. H. Yagüe, E. Soy, B. Q. Merino, J. Puig, M. B. Fabregat, and R. Colomer, “Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer.,” Clinical & Translational Oncology, vol. 7, no. 11, pp. 515–517, 2005. View at Google Scholar · View at Scopus
  15. L. M. Pasetto and S. Monfardini, “Is acute dyspnea related to oxaliplatin administration?” World Journal of Gastroenterology, vol. 12, no. 36, pp. 5907–5908, 2006. View at Google Scholar · View at Scopus
  16. K. H. Jung, S. Y. Kil, I. K. Choi et al., “Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX),” International Journal of Tuberculosis and Lung Disease, vol. 10, no. 10, pp. 1181–1182, 2006. View at Google Scholar · View at Scopus
  17. M. Garrido, A. O'Brien, S. González, J. M. Clavero, and E. Orellana, “Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report,” Chest, vol. 132, no. 6, pp. 1997–1999, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Ruiz-Casado, M. D. García, and M. A. Racionero, “Pulmonary toxicity of 5-fluoracil and oxaliplatin,” Clinical and Translational Oncology, vol. 8, no. 8, p. 624, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Mundt, H. C. Mochmann, H. Ebhardt, M. Zeitz, R. Duchmann, and M. Pauschinger, “Pulmonary fibrosis after chemotherapy with oxaliplatin and 5-fluorouracil for colorectal cancer,” Oncology, vol. 73, no. 3-4, pp. 270–272, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. S. A. Lobera, N. S. Mariñelarena, I. E. Echeberría et al., “Fatal pneumonitis induced by oxaliplatin,” Clinical and Translational Oncology, vol. 10, no. 11, pp. 764–767, 2008. View at Publisher · View at Google Scholar
  21. B. E. Wilcox, J. H. Ryu, and S. Kalra, “Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: a report of three cases,” Respiratory Medicine, vol. 102, no. 2, pp. 273–279, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Muneoka, Y. Shirai, M. Sasaki, T. Wakai, J. Sakata, and K. Hatakeyama, “Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX),” International Journal of Clinical Oncology, vol. 14, no. 5, pp. 457–459, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Ohori, M. Takahashi, N. Ogasawara, M. Suzuki, Y. Miyate, and S. Kato, “Two cases of interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX),” Gan To Kagaku Ryoho, vol. 36, no. 2, pp. 295–298, 2009. View at Google Scholar · View at Scopus
  24. C.-G. Ryu, E.-J. Jung, G. Kim, S. R. Kim, and D.-Y. Hwang, “Oxaliplatin-induced pulmonary fibrosis: two case reports,” Journal of the Korean Society of Coloproctology, vol. 27, no. 5, pp. 266–269, 2011. View at Publisher · View at Google Scholar
  25. A. K. Chan, B. A. Choo, and J. Glaholm, “Pulmonary toxicity with oxaliplatin and capecitabine/5-fluorouracil chemotherapy: a case report and review of the literature,” Onkologie, vol. 34, no. 8-9, pp. 443–446, 2011. View at Publisher · View at Google Scholar
  26. J. F. Cordier, “Cryptogenic organising pneumonia,” European Respiratory Journal, vol. 28, no. 2, pp. 422–446, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. C. I. Daïen, A. Monnier, P. Claudepierre et al., “Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases,” Rheumatology, vol. 48, no. 8, pp. 883–886, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Toussirot, J. M. Berthelot, E. Pertuiset et al., “Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-α- blocking agent: a case series,” Journal of Rheumatology, vol. 36, no. 11, pp. 2421–2427, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. D. A. Zisman, W. J. McCune, G. Tino, and J. P. Lynch, “Drug-induced pneumonitis: the role of methotrexate,” Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 18, no. 3, pp. 243–252, 2001. View at Google Scholar · View at Scopus
  30. R. A. Foster, D. S. Zander, P. J. Mergo, and J. F. Valentine, “Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations,” Inflammatory Bowel Diseases, vol. 9, no. 5, pp. 308–315, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. A. De Diego, M. C. Rogado, M. Prieto, D. Nauffal, and M. Perpina, “Disseminated pulmonary granulomas after intravesical bacillus Calmette-Guerin immunotherapy,” Respiration, vol. 64, no. 4, pp. 304–306, 1997. View at Google Scholar · View at Scopus
  32. Y. Saito and A. Gemma, “Current status of DILD in molecular targeted therapies,” International Journal of Clinical Oncology, vol. 17, no. 6, pp. 534–541, 2012. View at Publisher · View at Google Scholar